Interestingly, a recent preclinical study provided evidence that chimeric antigen receptor (CAR)-engineered natural killer (NK) cells able to target wild-type EGFR and EGFRvIII markedly enhance the killing of glioblastoma cell lines and patient-derived glioblastoma stem cells [296]. Here, EGFR is linked to glioblastoma.